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The Regulation of Type I Interferon Production 
by Paramyxoviruses
Stephen Goodbourn1 and Richard E. Randall2
Experimentally, paramyxoviruses are conventionally considered good inducers of type I interferons (IFN-α/β), 
and have been used as agents in the commercial production of human IFN-α. However, in the last few years 
it has become clear that viruses in general mount a major challenge to the IFN system, and paramyxoviruses 
are no exception. Indeed, most paramyxoviruses encode mechanisms to inhibit both the production of, and 
response to, type I IFN. Here we review our knowledge of the type I IFN-inducing signals (by so-called patho-
gen-associated molecular patterns, or PAMPs) produced during paramyxovirus infections, and discuss how 
paramyxoviruses limit the production of PAMPs and inhibit the cellular responses to PAMPs by interfering with 
the activities of the pattern recognition receptors (PRRs), mda-5, and RIG-I, as well as downstream components 
in the type I IFN induction cascades.
Introduction
Paramyxoviruses are small enveloped viruses with a single-stranded negative sense genome of 15–19 kb 
(reviewed by Lamb and Parks (2006)). The Paramyxoviridae 
family (see Fig. 1) includes a number of important disease-
causing viruses, including measles virus (MeV), mumps 
virus (MuV), the human parainfl uenza viruses (HPIV), and 
human respiratory syncytial virus (HRSV) of man, as well 
as Newcastle disease virus (NDV), bovine respiratory syn-
cytial virus (BRSV), rinderpest virus (RPV), turkey rhinotra-
cheitis virus (TRTV), and Sendai virus (SeV) of mammals 
and birds. Certain paramyxoviruses also have zoonotic 
potential (Wang and others 2001) observed during outbreaks 
of the newly emergent Hendra virus (HeV) and Nipah virus 
(NiV), which appear to have natural reservoirs in fruit bats 
but have also infected farm animals, domestic animals, and 
humans.
The life cycle of paramyxoviruses (reviewed in Lamb 
and Parks (2006)) takes place in the cytoplasm of infected 
cells after the viral nucleoprotein/genome complex has been 
introduced by a process of fusion between the cell mem-
brane and viral envelope. The 3′ terminus of genomic RNA 
has promoters for initiation of both virus transcription and 
replication whereas the 3′ terminus of antigenomic RNA 
only functions in replication. Viral transcription occurs 
when the viral polymerase binds to the 3′ promoter and 
processes along the template, producing fi rst a 5′-triphos-
phorylated leader sequence and then initiating stable tran-
scription at gene-specifi c sequences that fl ank each viral 
open-reading frame (ORF) to produce 5′-capped RNAs 
that are also polyadenylated by the polymerase (reviewed 
in Whelan and others (2004)). As expected from the small 
size of the viral genome, the paramyxoviruses have a lim-
ited genetic repertoire. All paramyxoviruses have genes 
encoding nucleoprotein (NP), phosphoprotein (P), matrix 
protein (M), fusion protein (F), attachment protein (HN for 
respiroviruses, rubulaviruses, and avulaviruses, H for mor-
billiviruses, and G for henipaviruses and members of the 
Pneumovirinae subfamily), and RNA-dependent RNA poly-
merase (L). Some of the rubulaviruses and avulaviruses, and 
all of the Pneumovirinae also encode a small protein called 
SH. Pneumoviruses and metapneumoviruses also contain 
an M2 gene, and in addition pneumoviruses have 2 genes 
that encode the nonstructural NS1 and NS2 proteins, whose 
function will be discussed later.
The number of proteins encoded by viruses within the 
subfamily Paramyxovirinae is larger than the number of genes 
contained in their genome, as their P genes have overlapping 
ORFs that give rise to multiple, distinct gene products (see 
Fig. 2). The morbilliviruses, respiroviruses, henipaviruses, 
and avulaviruses generate a primary transcript whose 
mRNA is translated authentically to generate the P protein; 
JOURNAL OF INTERFERON & CYTOKINE RESEARCH
Volume 29, Number 9, 2009
© Mary Ann Liebert, Inc.
DOI: 10.1089/jir.2009.0071
REVIEW
08-JIR-2009_0071.indd   539 8/27/2009   11:25:36 AM
GOODBOURN AND RANDALL540
“I.” Interestingly, in the rubulaviruses it is the V protein that 
is genomically templated, and production of the P protein 
requires an insertion of 2Gs into the mRNA by RNA editing; 
the addition of 1 or 4 Gs creates an mRNA for the I protein. In 
addition to these products, morbilliviruses, respiroviruses, 
and henipaviruses translate the P/V/W/D mRNAs using an 
alternative reading frame(s) to generate poorly conserved 
“C” protein(s); although only a single C protein is normally 
made, SeV can utilize 4 distinct start codons to generate C′, 
C, Y1, and Y2 proteins that have a different N-terminus but 
however, a unique process of “RNA editing” (also known as 
pseudo-template addition) can result in the insertion of G 
residues at an “editing site” in the middle of the transcript 
to generate mRNAs where there is a frameshift in the cod-
ing sequence downstream from this site. The insertion of a 
single G generates an mRNA that translates into a protein 
called the “V protein,” which has a common N-terminus to 
the P protein, but a unique C-terminus. The insertion of a 
second G residue creates an mRNA that encodes a protein 
with a different C-terminus called, variously, “W”, “D,” or 
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FIG. 1. Classifi cation of paramyxoviruses. The Paramyxoviridae family is divided into Paramyxovirinae and the Pneumovirinae 
subfamilies. The Paramyxovirinae subfamily contains fi ve genera: respiroviruses, rubulaviruses, henipaviruses, morbillivi-
ruses, and avulaviruses. The Pneumovirinae subfamily contains 2 genera: pneumoviruses and metapneumoviruses. This 
classifi cation is based predominantly on sequence homology and genome organization. Abbreviations: SeV, Sendai virus; 
HPIV, human parainfl uenza viruses; BPIV3, bovine parainfl uenza virus 3; MuV, mumps virus; SV5, simian virus 5; HeV, 
Hendra virus; NiV, Nipah virus; MeV, measles virus; CDV, canine distemper virus; RPV, rinderpest virus; PDV, phocine dis-
temper virus; NDV, Newcastle disease virus; APMVs, avian paramyxoviruses; HRSV, human respiratory syncytial virus; 
BRSV, bovine respiratory syncytial virus; HMPV, human metapneumovirus; TRTV, turkey rhinotrachetis virus.
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FIG. 2. Organization of the P/V/C genes of Paramyxovirinae and their relationship to their accessory proteins. (A) The 
P proteins of morbilliviruses, respiroviruses, and henipaviruses are translated from mRNAs produced as faithful copies 
of their P/V/C genes (green bar). Insertion of a single G at the RNA-editing site generates a transcript that encodes the V 
protein, and insertion of 2 G residues generates a transcript that encodes the W proteins and D proteins (HPIV3). The P, V, 
W, and D proteins share a common N-terminus (blue bar), but distinct C-termini (P = pink bar, V = light green bar, W and 
D = yellow bar). The C protein(s) (lilac bars) are generated by translation of the P/V/W/D mRNAs using alternative initi-
ation codons. Translation of the prototypical C protein begins at an AUG that resides downstream of P protein initiation 
codon, and the Y1 and Y2 proteins of Sendai virus are translated from AUGs that reside even further downstream. The C′ 
protein made by Sendai virus is translated from an ACG codon that resides 5′ to the AUG of the P protein. (B) The P proteins 
of avulaviruses are also translated from mRNAs produced as faithful copies of their P/V genes (green bar). Insertion of a 
single G at the RNA-editing site generates a transcript that encodes the V protein, and insertion of 2 G residues generates a 
transcript that encodes the I protein. (C) In contrast, the V proteins of rubulaviruses are translated from mRNAs produced 
as faithful copies of their P/V genes (green bar). Insertion of 1 or 4 G residues at the RNA-editing site generates a transcript 
that encodes the I protein, and insertion of 2 G residues generates a transcript that encodes the P protein.
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NDV. Despite this and despite the fact that the replicative 
strategies of the Paramyxoviridae are understood in detail 
(reviewed in Lamb and Parks (2006), Whelan and others 
(2004)), we know relatively little about the nature of the IFN-
inducing paramyxoviral PAMPs. Although paramyxoviruses 
effi ciently encapsidate both their genomic and antigenomic 
RNAs by linking the process of replication to encapsida-
tion, thereby “hiding” the free 5′ triphosphate on these 
molecules, they have nevertheless been shown to activate 
RIG-I (Kato and others 2006; Plumet and others 2007; Strahle 
and others 2007; Habjan and others 2008). Paramyxoviruses 
appear to generate little free dsRNA during the course of an 
infection (Weber and others 2006) and thus should also be 
poor activators of mda-5. Nevertheless, there are a number 
of reports that demonstrate that paramyxoviruses activate 
mda-5 (Andrejeva and others 2004; Yoneyama and others 
2004; Melchjorsen and others 2005; Yoneyama and others 
2005; Berghall and others 2006; Yount and others 2008) and, 
as discussed later, many paramyxoviruses encode products 
that interfere directly with mda-5.
One striking feature to emerge from studies on SeV is that 
plaque-purifi ed virus is a poor inducer of type I IFN, and that 
a good induction profi le only emerges when signifi cant lev-
els of defective interfering (DI) particles accumulate within 
the virus stock preparations (Johnston 1981; Poole and others 
2002); we have made similar observations for PIV5 and MuV 
(unpublished observations), and it has also been reported 
that vaccine strains of MeV are associated with the induc-
tion of type I IFN that correlates with DI particle production 
(Shingai and others 2007). DI particles generated by SeV are 
the best understood, and are of 2 types, internal deletion or 
copyback. The latter are generated by promoter exchange 
during replication and thus contain ssRNA with a terminal 
pan-handle of dsRNA. Internal deletion genomes lack seg-
ments of the viral genome but are otherwise normal. In a 
molecular analysis of type I IFN induction by SeV, Kolakfsky 
and colleagues have shown that induction is strongly corre-
lated to the levels of copyback genomes in their laboratory 
stocks and commercial preparations (Strahle and others 
2006); these particles have been shown to activate RIG-I 
(Strahle and others 2007). However, equivalent preparations 
of purifi ed DI particles of SeV are also strong activators of 
an mda-5-dependent antiviral innate immunity program in 
macrophages (Yount and others 2008). These studies raise 
an interesting question of what the physiological inducers 
of type I IFN really are during infections in vivo—are they 
PAMPs generated by the virus as a result of its normal repli-
cative strategy (we propose to call these “essential PAMPs”), 
or are they PAMPs generated as a result of aberrant tran-
scription or replication (“corrupted PAMPs”)? This question 
is also relevant when we consider virally encoded type I 
IFN antagonists—have these evolved to limit the action of 
“essential PAMPs,” or limit the activities of potentially more 
potent “corrupted PAMPs”? The issue about the potency of 
“essential” versus “corrupted PAMPs” also suggests that the 
strategies by which viruses control the fi delity of replication 
and transcription will have an important bearing on the 
control of type I IFN induction and viral fi tness.
Although the requirement for accessory proteins in gen-
erating fully virulent paramyxoviruses has long been appre-
ciated, a link to the IFN system was not established until 
relatively recently. Initially using PIV5 (formerly known as 
SV5), it was fi rst shown that PIV5 specifi cally blocks IFN 
a common C-terminus. The P genes of viruses within the 
Pneumovirinae subfamily do not encode more than 1 protein, 
but rather some of these viruses, including HRSV and BRSV, 
have 2 extra genes, NS1 and NS2 that, like the V and C pro-
teins, act as interferon (IFN) antagonists (see below).
The alternative products of the P gene are rarely essen-
tial for viral replication, leading to them being described 
as “luxury functions” or “accessory proteins,” but their 
deletion frequently leads to severe attenuation. Although 
this attenuation is primarily associated with a failure to 
control the host IFN response, these proteins have addi-
tional functions, as recombinant viruses that cannot make 
these accessory proteins often replicate poorly in “IFN-
compromised” cells. As discussed elsewhere in this issue 
(Ramachandran and Horvath 2009), many V and C proteins 
and the Pneumovirus NS1 and NS2 proteins have the capac-
ity to interfere with IFN signaling. However, blocking IFN 
signaling alone is not suffi cient to allow these viruses to 
fully circumvent the IFN response because if a virus only 
blocked IFN signaling, infected cells may still respond to 
infection by releasing large amounts of type I IFN. This 
would induce an antiviral state in surrounding uninfected 
cells, making it diffi cult for the virus to spread from the ini-
tial foci of infection (Andrejeva and others 2002; Carlos and 
others 2005; Precious and others 2007). Thus, paramyxovi-
ruses also attempt to limit type I IFN induction. Here we 
review this active area of research.
Paramyxoviruses and Type I IFN Induction
As discussed elsewhere in this volume (Gale and Sen 
2009), the induction of type I IFN is brought about by 
the detection of pathogen-associated molecular patterns 
(PAMPs) by pattern recognition receptors (PRRs) in infected 
cells. Viral PAMPs are usually nucleic acids with structures 
not found in uninfected cells, such as dsRNA or uncapped 
ssRNA with a 5′ triphosphate, although it has been reported 
that HRSV can induce type I IFN through TLR4 via recog-
nition of its F protein (Kurt-Jones and others 2000; Haynes 
and others 2001). Viral nucleic acids can become associated 
with PRRs present either in endosomes as a result of endo-
cytosis of virus particles/extracellular debris or autophagy 
of cytoplasmic material (dsRNA, ssRNA, or CpG DNA, rec-
ognized by TLR3, TLR7, and TLR9, respectively), or in the 
cytoplasm where they are recognized by the related RNA 
helicases, RIG-I and mda-5. Our knowledge of the nature 
of the ligands for RIG-I and mda-5 is incomplete, although 
the current consensus is that RIG-I responds to ssRNAs con-
taining uncapped 5′ triphosphorylated ends (Hornung and 
others 2006; Pichlmair and others 2006; Cui and others 2008; 
Takahasi and others 2008) and short dsRNA molecules (Kato 
and others 2008), whereas mda-5 responds to longer dsRNA 
molecules (Kato and others 2008). Once activated, RIG-I and 
mda-5 interact with a common adaptor VISA (also known 
as Cardif/MAVS/IPS-1) through an N-terminal CARD 
domain. Recruitment of VISA initiates the activation of the 
transcription factors IRF-3 and NF-κB and ultimately results 
in the transcription of proinfl ammatory cytokine genes such 
as IFN-β (reviewed in Randall and Goodbourn (2008), Gale 
and Sen (2009)).
A considerable number of studies on the regulation of 
type I IFN induction have used laboratory preparations of 
paramyxoviruses as potent inducers, especially SeV and 
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in Figure 3. Additionally, it is becoming increasingly clear 
that viral products actively limit the production of PAMPs 
by regulating viral transcription and replication.
V Proteins
The role of mda-5 as a PRR was fi rst unveiled by studies 
on the V proteins of paramyxoviruses; the V proteins of most 
paramyxoviruses are able to antagonize both the NF-κB and 
IRF-3 arms of the dsRNA signaling responses (Poole and 
others 2002; Childs and others 2007), and mda-5 was identi-
fi ed as an interacting partner for the V proteins of, initially, 
PIV5 (Andrejeva and others 2004), but subsequently HPIV2, 
MuV, SeV, MeV, HeV, NiV, Menangle virus, Mapuera virus, 
Salem virus, Porcine rubulavirus, Tioman virus, and NDV 
(Andrejeva and others 2004; Childs and others 2007). The 
interaction with mda-5 was shown to require the cysteine-
rich C-terminus of the V protein, which is the only region 
of the V protein that shows signifi cant conservation, and for 
signaling by targeting STAT1 for proteasome-mediated deg-
radation (Didcock and others 1999a, 1999b) and, later, that it 
also specifi cally blocks type I IFN production (He and oth-
ers 2002; Poole and others 2002; Wansley and Parks 2002). 
Subsequent studies have shown that these observations hold 
true for most other paramyxoviruses (effects of paramyxo-
viruses on IFN signaling are reviewed in Ramachandran 
and Horvath (2009)). The ability to regulate the produc-
tion of type I IFN also appears to be a common feature of 
paramyxoviruses, and a number of studies have demon-
strated that viruses bearing deletions of the V gene and/
or the C gene have the phenotype of enhanced type I IFN 
production (see below). These studies were often unable to 
distinguish between viral functions that controlled the gen-
eration of PAMPs from those that encoded specifi c type I IFN 
antagonists. However, analyses of the properties of individ-
ually expressed genes have demonstrated that a number of 
them possess the ability to directly interfere with type I IFN 
induction. This will be discussed later and is summarized 
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FIG. 3. Paramyxovirus acces-
sory proteins target the intracel-
lular viral pathogen-associated 
molecular patterns (PAMP) 
signaling pathways. The signal-
ing pathways leading from the 
RNA helicases mda-5 and RIG-I 
to IFN-β induction are shown 
(reviewed in Randall and 
Goodbourn (2008), Gale and Sen 
(2009)). As discussed in the text, 
paramyxovirus V proteins inter-
act with mda-5 and prevent its 
activation. Sendai virus (SeV) C 
protein targets RIG-I, although 
a specifi c molecular interaction 
has yet to be shown. The NS2 
protein of human respiratory 
syncytial virus (HRSV) directly 
binds to RIG-I and inhibits 
its activity. The V proteins of 
human parainfl uenza virus 2 
(HPIV2), simian virus 5 (PIV5, 
formerly SV5), and mumps 
virus (MuV) interact with and 
inhibit TBK1 and IKK-ε, and 
NiV V inhibits IKK-ε (although 
not TBK1). The C protein of rin-
derpest virus (RPV) and the W 
protein of Nipah virus (NiV) 
have uncharacterized nuclear 
targets that act downstream of 
transcription factors.
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V can bind directly to IRF-7 and inhibit its transactivation 
potential (Pfaller and Conzelmann 2008).
Clearly, it is important that paramyxoviruses tightly con-
trol the type, quantity, and temporal production of PAMPs 
during their replication cycle. For example, it would be 
advantageous to limit the production of PAMPs prior to the 
synthesis of specifi c antagonists. The control of virus tran-
scription and replication is complicated (reviewed in Whelan 
and others (2004), Lamb and Parks (2006)) with many pro-
teins, including NP, P, and L, being involved, and hence the 
function of any of these proteins may potentially infl uence 
the generation of PAMPs. The V proteins of paramyxovi-
ruses may also play an indirect role in controlling type I IFN 
induction. It is notable that a number of paramyxovirus V 
proteins have been shown to inhibit viral RNA synthesis in 
minireplicon systems (Curran and others 1991; Curran and 
others 1995; Horikami and others 1997; Lin and others 2005; 
Parks and others 2006; Witko and others 2006; Nishio and 
others 2008), and recombinant viruses with mutations in 
their V proteins often show increased viral RNA synthesis 
(Delenda and others 1997; Kato and others 1997; Schneider 
and others 1997; Tober and others 1998; Durbin and oth-
ers 1999; Baron and Barrett 2000; Kawano and others 2001; 
Gainey and others 2008). The V proteins may help limit the 
production of PAMPs by binding soluble NP (Precious and 
others 1995; Curran and others 1995; Horikami and others 
1997; Tober and others 1998), thereby infl uencing the control 
of virus transcription and replication, and thus helping to 
limit the amount of protein-free viral RNA in the cytoplasm. 
Additionally, PIV5 V negatively regulates the P subunit of 
the viral RNA polymerase by directly interacting with the 
kinase Akt1 and inhibiting its ability to phosphorylate the 
P protein (Sun and others 2008). The ability of the V protein 
to negatively regulate the activity of the P protein appears of 
paramount importance in controlling PIV5 viral RNA syn-
thesis (Timani and others 2008). Paramyxovirus V proteins 
may play other roles in regulating viral replication; HPIV2 V 
binds to the large RNA polymerase (L) protein (ie, the major 
RNA polymerase subunit) and inhibits replication (Nishio 
and others 2008).
C Proteins
The phenotypes of respiroviruses, morbilliviruses, and 
henipaviruses lacking the C ORF have shown that the C 
protein(s) play direct and indirect (by controlling virus 
transcription and replication—see below) roles in limiting 
type I IFN induction. SeV mutants unable to express either 
the V gene or the C gene show elevated levels of host type I 
IFN production (Strahle and others 2003; Komatsu and oth-
ers 2004; Strahle and others 2006). The product of the SeV 
C open-reading frame can directly limit type I IFN induc-
tion (Komatsu and others 2004) and it has been recently 
proposed that the C proteins of SeV can act to inhibit RIG-I 
(Strahle and others 2007), although it is not known if this 
inhibition is direct. The SeV C protein has also been shown 
to be a negative regulator of viral RNA polymerase (Curran 
and others 1991; Curran and others 1992; Cadd and others 
1996; Horikami and others 1997), as has the C protein of the 
related HPIV3 (Malur and others 2004), and again thus may 
infl uence the generation of PAMPs.
MeV that cannot express the C protein also induces more 
type I IFN than the wild-type virus (Nakatsu and others 
each of the V proteins tested, the interaction inhibits activa-
tion of mda-5 (Childs and others 2007)—see Figure 3. In con-
trast, RIG-I does not appear to be an interaction partner for 
the V proteins examined (Childs and others 2007). By anal-
ogy to RIG-I (Cui and others 2008; Takahasi and others 2008), 
the activation of mda-5 requires the binding of dsRNA to 2 
separate sites (one at the C-terminus and one in the helicase 
domain), which triggers multimerization (Childs and others 
2009) and a conformational change leading to the formation 
of an mda-5 structure that enables the N-terminal CARD 
domains to align in such a way as to permit recruitment 
of the VISA adaptor molecule. The PIV5 V protein binds to 
several sites on mda-5 within the C-terminus and helicase 
domain, thus preventing the RNA from binding and the 
activated multimer from forming (Childs and others 2009). 
Whilst most paramyxovirus V proteins bind mda-5, it is not 
a universal feature, since the V protein of RPV does not inter-
act with mda-5 (Boxer and others 2009). Furthermore, HPIV3 
does not encode a V protein as the RNA-editing event within 
the Respirovirus HPIV3 P gene generates a protein that is 
truncated before the cysteine-rich C-terminus.
As discussed earlier, there is a signifi cant body of evi-
dence that indicates that paramyxoviruses can induce type 
I IFN through the activation of RIG-I as well mda-5, and 
therefore it seems reasonable that they encode products to 
block RIG-I activation of the type I IFN induction cascade. In 
this regard it is of note that it has recently been reported that 
the V proteins of the rubulaviruses, PIV5, HPIV2, and MuV 
inhibit TBK1 and IKK-ε (Lu and others 2008), kinases which 
reside downstream of both mda-5 and RIG-I in the type I 
IFN induction cascade (see Fig. 3). The interaction between 
the V proteins and TBK1/IKK-ε appears to be direct and 
under these circumstances the V proteins become a decoy 
substrate to prevent the phosphorylation of IRF-3. However, 
these interactions may be a cell type-specifi c effect since 
V does not inhibit TLR3, TRIF, TBK1, or RIG-I signaling in 
some cell lines tested (Hilton and others 2006; Childs and 
others 2007). The V protein of NiV has also been shown to be 
able to inhibit transactivation by IKK-ε but not TBK1 (Shaw 
and others 2005), although no biochemical characterization 
of this phenomenon is available (see Fig. 3).
A recent observation suggests that the V proteins of some 
paramyxoviruses may have further functions in blocking 
type I IFN induction. MeV is highly immunotropic and 
possesses the ability to infect both plasmacytoid and con-
ventional dendritic cells (pDCs and cDCs). The former are 
a major source of systemic type I IFN during many viral 
infections and MeV has been shown to be able to profoundly 
down-regulate type I IFN production by TLR7 and TLR9 
agonists in these cells (Schlender and others 2005). pDCs 
appear to be unusual in that they constitutively express 
high levels of IRF-7, and in contrast to the signaling pathway 
described in Figure 3, pDCs activate type I IFN transcription 
through a distinct pathway that leads to the phosphoryla-
tion of IRF-7. The signaling pathway requires that ligand-
activated TLR7 or TLR9 recruits MyD88, which in turn 
recruits a complex containing TRAF3, TRAF6, IRAK1, and 
IRAK4 and leads to the activation of IKK-α that ultimately 
phosphorylates IRF-7 (see Fig. 3 in Randall and Goodbourn 
2008). Pfaller and Conzelmann have recently shown that the 
V protein of MeV can block the IKK-α-mediated activation 
of IRF-7 by directly binding to IKK-α and acting as a decoy 
substrate (Pfaller and Conzelmann 2008). Additionally, MeV 
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amounts from infected cells (Hendricks and others 1988). As 
well as its other functions (reviewed in Collins and Graham 
(2008)), the G protein also inhibits innate responses, includ-
ing infl ammatory cytokines and IFN (Polack and others 2005; 
Shingai and others 2008) by inhibiting TLR3/4-mediated 
activation. Whilst sG does not effect signaling through the 
RIG-I/mda-5 pathway, it does inhibit the TLR adaptor TRIF/
TICAM-1 pathway. The need for RSV to inhibit these path-
ways may be related to fact that, in contrast to sG, the RSV 
F protein activates TLR4 signaling (Kurt-Jones and others 
2000; Haynes and others 2001).
Conclusions
Despite their limited coding capacity, paramyxoviruses 
have had to evolve mechanisms to circumvent the IFN sys-
tem. Interestingly, the specifi c mechanisms by which even 
very closely related viruses achieve this can differ subtly and 
clearly these differences must infl uence the types of diseases 
these viruses cause. Nevertheless, the way in which paramyx-
oviruses try to circumvent the IFN response can basically be 
considered as (i) limiting the production of PAMPs, (ii) inhib-
iting specifi c cellular components in the type I IFN induc-
tion cascade (with mda-5 being a near universal target for all 
members of the Paramyxovirinae subfamily), and (iii) block-
ing IFN signaling (Ramachandran and Horvath 2009). To 
date, other than by limiting the amount of PAMPs (such as 
dsRNA) that can activate enzymes such as PKR with antiviral 
activity, there is no evidence of paramyxovirus products that 
directly inhibit IFN-induced proteins with antiviral activ-
ity. However, despite these evasion mechanisms, it is clear 
that paramyxoviruses cannot completely circumvent the IFN 
response, and the IFN system remains critical in controlling 
paramyxovirus infections, buying time for the generation of 
an adaptive immune response.
Although much has been learnt in recent years about how 
paramyxoviruses limit the production of type I IFN, there 
are still signifi cant gaps in our knowledge. For example, we 
have a poor understanding of the molecular structures of 
the PAMPs that stimulate type I IFN induction in natural 
infections, and whether they are what we term “essential 
PAMPs” or “corrupted PAMPs.” It is interesting to specu-
late that where paramyxoviruses have been used to induce 
type I IFN in experimental animals; the observed induction 
may be due to the occurrence of “corrupted PAMPs,” such 
as those produced by DI particles. Furthermore, it remains 
unclear what the main sources of IFN are within an infected 
animal, and which cells are infected by any specifi c para-
myxovirus. Hence, the knowledge gained from studies on 
the induction of type I IFN from continuous cell lines may 
be only an approximation of the situation in response to 
paramyxovirus infections in vivo.
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